Literature DB >> 9521326

Fas-mediated apoptosis and activation-induced T-cell proliferation are defective in mice lacking FADD/Mort1.

J Zhang1, D Cado, A Chen, N H Kabra, A Winoto.   

Abstract

Programmed cell death, or apoptosis, is important in homeostasis of the immune system: for example, non-functional or autoreactive lymphocytes are eliminated through apoptosis. One member of the tumour necrosis factor receptor (TNFR) family, Fas (also known as CD95 or Apo-1), can trigger cell death and is essential for lymphocyte homeostasis. FADD/Mort1 is a Fas-associated protein that is thought to mediate apoptosis by recruiting the protease caspase-8. A dominant-negative mutant of FADD inhibits apoptosis initiated by Fas and other TNFR family members. Other proteins, notably Daxx, also bind Fas and presumably mediate a FADD-independent apoptotic pathway. Here we investigate the role of FADD in vivo by generating FADD-deficient mice. As homozygous mice die in utero, we generated FADD-/- embryonic stem cells and FADD-/- chimaeras in a background devoid of the recombination activating gene RAG-1, which activates rearrangement of the immunoglobulin and T-cell receptor genes. We found that thymocyte subpopulations were apparently normal in newborn chimaeras. Fas-induced apoptosis was completely blocked, indicating that there are no redundant Fas apoptotic pathways. As these mice age, their thymocytes decrease to an undetectable level, although peripheral T cells are present in all older FADD-/- chimaeras. Unexpectedly, activation-induced proliferation is impaired in these FADD-/- T cells, despite production of the cytokine interleukin (IL)-2. These results and the similarities between FADD-/- mice and mice lacking the beta-subunit of the IL-2 receptor suggest that there is an unexpected connection between cell proliferation and apoptosis.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9521326     DOI: 10.1038/32681

Source DB:  PubMed          Journal:  Nature        ISSN: 0028-0836            Impact factor:   49.962


  209 in total

Review 1.  Signal transduction by tumour necrosis factor and tumour necrosis factor related ligands and their receptors.

Authors:  B G Darnay; B B Aggarwal
Journal:  Ann Rheum Dis       Date:  1999-11       Impact factor: 19.103

2.  Thymocyte apoptosis.

Authors:  Y Yang; J D Ashwell
Journal:  J Clin Immunol       Date:  1999-11       Impact factor: 8.317

Review 3.  A portrait of the Bcl-2 protein family: life, death, and the whole picture.

Authors:  M Pellegrini; A Strasser
Journal:  J Clin Immunol       Date:  1999-11       Impact factor: 8.317

4.  Activation of Fas by FasL induces apoptosis by a mechanism that cannot be blocked by Bcl-2 or Bcl-x(L).

Authors:  D C Huang; M Hahne; M Schroeter; K Frei; A Fontana; A Villunger; K Newton; J Tschopp; A Strasser
Journal:  Proc Natl Acad Sci U S A       Date:  1999-12-21       Impact factor: 11.205

5.  Morphological changes in the nucleus and actin cytoskeleton in the process of Fas-induced apoptosis in Jurkat T cells.

Authors:  W Maruyama; S Irie; T A Sato
Journal:  Histochem J       Date:  2000-08

6.  MAPK/ERK signaling in activated T cells inhibits CD95/Fas-mediated apoptosis downstream of DISC assembly.

Authors:  T H Holmström; I Schmitz; T S Söderström; M Poukkula; V L Johnson; S C Chow; P H Krammer; J E Eriksson
Journal:  EMBO J       Date:  2000-10-16       Impact factor: 11.598

7.  Mechanisms of apoptosis.

Authors:  J C Reed
Journal:  Am J Pathol       Date:  2000-11       Impact factor: 4.307

Review 8.  Death receptors couple to both cell proliferation and apoptosis.

Authors:  Ralph C Budd
Journal:  J Clin Invest       Date:  2002-02       Impact factor: 14.808

9.  T cell-specific FADD-deficient mice: FADD is required for early T cell development.

Authors:  N H Kabra; C Kang; L C Hsing; J Zhang; A Winoto
Journal:  Proc Natl Acad Sci U S A       Date:  2001-05-15       Impact factor: 11.205

Review 10.  The many roles of FAS receptor signaling in the immune system.

Authors:  Andreas Strasser; Philipp J Jost; Shigekazu Nagata
Journal:  Immunity       Date:  2009-02-20       Impact factor: 31.745

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.